Risk talk:: rhetorical strategies in consultations on hormone replacement therapy

被引:11
|
作者
Hoffmann, M
Linell, P
Lindh-Åstrand, L
Kjellgren, KI
机构
[1] Linkoping Univ, Dept Med & Care, Div Clin Pharmacol, SE-58183 Linkoping, Sweden
[2] Linkoping Univ, Dept Commun Studies, SE-58183 Linkoping, Sweden
[3] Linkoping Univ, Dept Mol & Clin Med, Div Obstet & Gynecol, SE-58183 Linkoping, Sweden
[4] Gothenburg Univ, Sahlgrenska Acad, Fac Hlth & Caring Sci, Inst Nursing, SE-40530 Gothenburg, Sweden
关键词
risk; communication; menopause; hormone replacement therapy; physician-patient relations;
D O I
10.1080/1369857031000123920
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
When analysing risk discussions in medical settings it is important to consider the specific activity type. In this qualitative study 20 first-time consultations by healthy women regarding hormone replacement therapy (HRT) in the menopause the risk discussion is asymmetrical with the doctors dominating. Despite being set up as a specific opportunity for women in the menopause to discuss problems and risks, it comes forth as a decision-making activity in a traditional medical setting. The consultations fulfil to a high extent the demands for informed decision making, but the risk discussions are recontextualised into a cost-benefit discourse with a typical implicit quantitative bias. The doctors use several different rhetorical strategies such as positive introduction of HRT, embedding drawbacks in positive introductions and/or exits thereby diminishing them. The word risk is avoided to a considerable extent and the term 'drawbacks' is used instead. The most obvious strategy is to move from the woman's symptoms to aspects of prevention, thus changing the discussion from the menopause and different strategies to cope with menopausal problems into a medically oriented discussion of pharmacological treatment alternatives. The 'change of life' in these talks is entirely conceptualised within a 'medical model'.
引用
收藏
页码:139 / 154
页数:16
相关论文
共 50 条
  • [41] Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers
    Gorman, Megan
    Shih, Karin
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2025, 26 (03) : 179 - 186
  • [42] Hormone replacement therapy and lung cancer risk in women: a meta-analysis of cohort studies Hormone replacement therapy and lung cancer risk
    Jin, Chao
    Lang, Baoping
    MEDICINE, 2019, 98 (51)
  • [43] Menopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis
    Liu, Yang
    Ma, Lan
    Yang, Xiaoling
    Bie, Jia
    Li, Dongya
    Sun, Chunyi
    Zhang, Jie
    Meng, Yushi
    Lin, Jie
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [44] Hormone replacement therapy and climacterium symptoms
    Ruszkowska, Barbara
    Malecka, Beata
    Maciejewski, Jerzy
    Rosc, Danuta
    FAMILY MEDICINE AND PRIMARY CARE REVIEW, 2009, 11 (03) : 741 - 742
  • [45] Unscheduled bleeding with hormone replacement therapy
    Dave, Fulva Gajjar
    Adedipe, Tolu
    Disu, Stewart
    Laiyemo, Raphael
    OBSTETRICIAN & GYNAECOLOGIST, 2019, 21 (02) : 95 - 101
  • [46] Hormone replacement therapy today: an update
    Lello, S.
    GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2007, 29 (12): : 393 - 397
  • [47] Hormone replacement therapy 2004 - The dilemma
    Flatau, E
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2004, 6 (10): : 642 - 642
  • [48] Hormone replacement therapy and venous disease
    de Castro Santos, M. E. Renno
    ACTA CHIRURGICA BELGICA, 2006, 106 (06) : 659 - 661
  • [49] THE ROLE OF PROGESTINS IN HORMONE REPLACEMENT THERAPY
    LOBO, RA
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (06) : 1997 - 2004
  • [50] Hormone replacement therapy and intraocular pressure
    Sator, MO
    Joura, EA
    Frigo, P
    Kurz, C
    Metka, H
    Hommer, A
    Huber, JC
    MATURITAS, 1997, 28 (01) : 55 - 58